Sunil flipping you off is enough.
Nobody is jealous of a delusional moron.
INO a P3 trial ..... HaHaHAhA..... not in your life time.
Sunil is flipping you off, you are just to dumb to know it.
Sunil is an imbecile and so are you.
You're both holding bags of dung.
You are probably dumber, if that's possible, you paid for your bag of dung.
What's that all about?
Sunil awarded himself FREE shares. He bought less than probably what you hold.
He's not risking anything.
After you get wiped out, Sunil will take a job at Apple Tree.
The Vegas line is 70 - 1 that additional trials won't be required.
The over/under closing price after announcement is 25 cents.
Is there any prohibition on Titan putting out a PR about what transpired at the meeting before the minutes are released? If the meeting went positively, wouldn't Sunil be tooting his own horn already, as at the conference calls, getting high fives and accepting congratulatory adulation? And when there is bad news, Sunil doesn't take questions at the conferences calls. The silence points to additional trials will be required and Sunil is probably already shopping for another massively dilutive financing. 20M shares and 40M more warrants? Merry Christmas! ( "Bah Humbug!", is probably more appropriate.)
ROW? There has been no mention that they are doing anything with ROW. Have they even filed an MA in the EU? No! Remember, Sunil can't multitask. Push pain overseas? A P2 and P3 trials are needed first. Then an MA needs to be approved.
The potential is getting greater by the day that additional Probuphine trials will be needed in the US and additional massive dilution will follow soon thereafter.
If synthetic worked, Inovio would have a product on the market.
They can't even reach P3.
Blue Bell, PA – December 13, 2007 –
VGX Pharmaceuticals announced today that it has completed the multi-site, multi-dose, and double-blind Phase II study for assessing the safety and antiviral effects of VGX- 410C, its lead product candidate for treating HCV infection. The data showed that VGX- 410C did not meet the efficacy endpoint of the study.
There' practically nothing in the pipeline.
The early stage #$%$ shoot would take a decade to develop and probably fail.